)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals (600276) investor relations material
Jiangsu Hengrui Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
9M revenue rose 5.26% YoY to RMB24.41bn; net income attributable to shareholders increased 20.38% to RMB6.92bn, supported by licensing income and innovation-led growth.
Q3 revenue grew 20.55% YoY to RMB8.95bn; attributable net income rose 88.92% to RMB2.46bn.
Financial highlights
9M adjusted net income, excluding nonrecurring items, increased 11.70% YoY to RMB6.24bn; Q3 adjusted net income rose 90.93% to RMB2.51bn.
9M operating cash flow was RMB7.84bn, down 13.90% YoY; Q3 operating cash flow increased 21.76% to RMB5.86bn.
9M total profit reached RMB7.73bn, up 20.53% YoY; Q3 total profit was RMB2.78bn, up 103.97%.
Outlook and guidance
Full-year innovation-drug sales growth is expected to fall short of the target set at the start of the year, despite improved Q3 growth.
Q4 priorities include accelerating new-product access and academic promotion to support faster revenue growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jiangsu Hengrui Pharmaceuticals
- Net profit up 21.69% to RMB 7.71B, fueled by innovation and global expansion.600276
H2 2025 - H1 2026 revenue fell 1.94% but innovative drug sales and R&D investment surged.600276H1 2026
- Q1 2026 saw double-digit profit and revenue growth, led by innovative drug sales and R&D advances.600276Q1 2026
- Q3 2025 saw double-digit revenue and profit growth, with strong cash flow and capital inflows.600276Q3 2025
- Net profit surged 29.67% on robust innovative drug sales and global licensing income.600276H1 2025
- Nine-month net profit jumped 32.98% on strong licensing income and robust revenue growth.600276Q3 2024
- Net profit surged 48.67% on 21.78% revenue growth, led by innovative drugs and licensing income.600276H1 2024
- Q1 profit surged on a one-time IDEAYA payment, while operating cash flow declined.600276Q1 2025
- Net profit up 47%, revenue up 22.6% year-over-year, with strong innovation and global growth.600276H2 2024
Next Jiangsu Hengrui Pharmaceuticals earnings date
H2 202625 Mar, 2027
Jiangsu Hengrui Pharmaceuticals
Next Jiangsu Hengrui Pharmaceuticals earnings date
H2 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Jiangsu Hengrui Medicine Co., Ltd. is a China-based pharmaceutical company engaged in the research, development, production, and distribution of innovative medicines. The company focuses on therapeutic areas such as oncology, anesthesiology, cardiology, and endocrinology. It offers a diverse portfolio of pharmaceutical products, including chemical drugs, biologics, and injectables. The company is headquartered in Lianyungang, China, and its shares are listed on the Shanghai Stock Exchange.